Loading...
•
Mar 31, 2025
Treace Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025.
Key Takeaways
Treace Medical Concepts reported solid growth in the first quarter of 2025 with a 3% increase in revenue to $52.6 million and significant improvements in adjusted EBITDA and net loss compared to the same period in the previous year. The company also expanded its bunion technology portfolio with new product launches and continued to build clinical evidence.
Generated revenue of $52.6 million in the first quarter 2025, representing growth of 3% over the same period in 2024.
Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024.
Improved adjusted EBITDA by 53% to $(3.8) million in the first quarter 2025 compared to $(8.3) million in the same period in 2024.
Expanded bunion technology portfolio through limited market releases of new systems and expects additional launches in 2025.
Forward Guidance
The company is reaffirming full-year 2025 revenue guidance and continues to expect breakeven Adjusted EBITDA for the full year.
Positive Outlook
- Reaffirming full-year 2025 revenue guidance of $224 million to $230 million, representing growth of 7% to 10% over 2024.
- Continues to expect breakeven Adjusted EBITDA for the full-year 2025.
- Expanding best in class bunion portfolio and robust innovation pipeline.
- Significant surgeon training momentum.
- Positioned for accelerating growth throughout the year.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- No specific negative forward guidance points were explicitly stated in the provided text.
- No specific negative forward guidance points were explicitly stated in the provided text.
- No specific negative forward guidance points were explicitly stated in the provided text.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...